A Comparison between the Two Surfactants, Beracsurf and Curosurf, in the  Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants

Zoheir  Fardid; Seyed Reza  Mirjalili; Mahmood  Noorishadkam; Mahmood  Vakili; Maryam  Saeida-Ardekani; Mohamad Hosein  Lookzadeh

doi:10.18502/wjpn.v8i1.21585

Zoheir Fardid Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Seyed Reza Mirjalili Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Mahmood Noorishadkam Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Mahmood Vakili Department of Community and Preventive Medicine, Health Monitoring Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Maryam Saeida-Ardekani Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Mohamad Hosein Lookzadeh Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

DOI: https://doi.org/10.18502/wjpn.v8i1.21585

Keywords: Respiratory Distress Syndrome; Premature Infant; Pulmonary Surfactants; Beractant; Poractant Alfa; Treatment Outcome

Abstract

Background: Respiratory distress syndrome (RDS) in premature infants results from surfactant deficiency. Given the high cost and limited availability of Curosurf, we compared its outcomes with the Iranian surfactant Beracsurf.

Methods: This descriptive cross-sectional study included premature infants (≤34 weeks) with RDS who met surfactant criteria. We assessed hospitalization duration, mechanical ventilation time, delivery mode, CPAP duration, Apgar score, gestational age, and clinical outcomes (discharge/mortality). Complications (pneumothorax, pulmonary/intraventricular hemorrhage, BPD, ROP, NEC), surfactant redosing frequency, and time to FiO₂<40% were compared between groups.

Results: A total of 80 infants were divided into two equal groups (40 each). Baseline demographics were similar (P>0.05). Beracsurf recipients required significantly longer mechanical ventilation (3.25 vs. 2.22 days, P=0.01) and CPAP (3.05 vs. 2.41 days, P=0.04) than Curosurf recipients. No significant differences were observed in other complications, hospitalization duration, or mortality.

Conclusion: Curosurf provided significantly shorter durations of respiratory support compared to Beracsurf. Other outcomes and complication rates were comparable. Further large-scale studies are warranted to guide clinical and economic decisions.